By Jack Barnes
Medical Marijuana, Inc., major investment company AXIM® Biotechnologies, Inc. (OTC: AXIM) was featured on a CBS New York News segment about the Company’s clinical trials for its CanChew Plus® cannabidiol (CBD) chewing gum for the treatment of patients with irritable bowel syndrome (IBS), a disease that affects up to 15% of the world population.
The segment includes an in-depth interview with CEO of AXIM® Biotechnologies Dr. George E. Anastassov, MD, DDS, MBA about the functionality of CanChew Plus® and AXIM® CTO Lekhram Changoer about how the double-blind, placebo-controlled trial is being conducted at Wageningen University in the Netherlands. In addition, the report interviews a CanChew® customer who gives testimony to the product’s positive effects for gout and IBS.
“It’s motivating to see national news coverage on AXIM, a company that is making an impact on the well-being of individuals through products that treat conditions for which there is currently no effective remedy,” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. “This trial is definitely newsworthy, as it’s the first advancement in cannabinoid research for treatment of IBS in medical history. We’re excited to see AXIM continually reaching milestones in its clinical development program.”
IBS is the most common disorder diagnosed by gastroenterologists and accounts for up to 12% of total visits to primary care providers, accounting for between 2.4 – 3.5 million annual physician visits in the United States alone.
Want to submit something? Click Here
Need promotion? Click Here
Follow me: Getmybuzzup on Twitter | Getmybuzzup on Facebook | Getmybuzzup on Google+ | Getmybuzzup on Tumblr | Getmybuzzup on Linkedin | Getmybuzzup on Pinterest | Getmybuzzup on Instagram | Getmybuzzup on Snapchat
Let us know what you think in the comment area below.
Liked this post? Subscribe to my RSS feed and get loads more!”